Profile data is unavailable for this security.
About the company
XTL Biopharmaceuticals Ltd is an Israel-based biopharmaceutical company engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
- Revenue in USD (TTM)0.00
- Net income in USD-1.78m
- Incorporated1993
- Employees0.00
- LocationX T L Biopharmaceuticals Ltd5 Badner St.,P.O.Box 8241RAMAT GAN 5218102IsraelISR
- Phone+972 99557080
- Fax+972 99519708
- Websitehttps://www.xtlbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kiora Pharmaceuticals Inc | 0.00 | -13.04m | 13.15m | 12.00 | -- | 0.6319 | -- | -- | -2.98 | -2.98 | 0.00 | 0.7929 | 0.00 | -- | -- | 0.00 | -77.27 | -70.52 | -91.06 | -81.86 | -- | -- | -- | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
| Monopar Therapeutics Inc | 0.00 | -8.40m | 13.30m | 10.00 | -- | 2.03 | -- | -- | -0.612 | -0.612 | 0.00 | 0.3749 | 0.00 | -- | -- | 0.00 | -81.69 | -54.07 | -107.13 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
| Actavia Life Sciences Inc | 0.00 | -4.44m | 13.35m | 1.00 | -- | -- | -- | -- | -0.0074 | -0.0074 | 0.00 | -0.0027 | 0.00 | -- | -- | 0.00 | -10,235.89 | -158.17 | -- | -- | -- | -- | -- | -- | -- | -21.20 | -- | -- | -- | -- | -547.04 | -- | -- | -- |
| Dominari Holdings Inc | 2.04m | -22.88m | 13.41m | 26.00 | -- | 0.2534 | -- | 6.58 | -4.44 | -4.44 | 0.3899 | 8.92 | 0.0305 | -- | 0.3829 | 78,423.08 | -34.20 | -26.82 | -35.10 | -27.45 | -- | -- | -1,122.22 | -3,353.52 | -- | -- | 0.00 | -- | -- | 135.75 | 12.72 | -- | 63.99 | -- |
| Lotus Pharmaceuticals Inc | 70.79m | 1.72m | 13.47m | 233.00 | 0.0904 | 0.0014 | 3.49 | 0.1903 | 0.0553 | 0.0553 | 2.56 | 3.58 | 0.6321 | 37.27 | 17.85 | 303,836.90 | 1.55 | 22.84 | 1.71 | 26.40 | 35.10 | 41.62 | 2.45 | 19.93 | 0.4428 | 30.80 | 0.0516 | 0.00 | 28.71 | 31.70 | -12.22 | 51.11 | 70.48 | -- |
| Coeptis Therapeutics Holdings Inc | 0.00 | -21.27m | 13.53m | 5.00 | -- | 3.07 | -- | -- | -0.8922 | -0.8922 | 0.00 | 0.1221 | 0.00 | -- | -- | 0.00 | -266.05 | -36.90 | -392.90 | -37.81 | -- | -- | -- | -- | -- | -- | 0.2068 | -- | -- | -- | 43.40 | -- | -- | -- |
| Pieris Pharmaceuticals Inc | 42.81m | -24.54m | 13.65m | 46.00 | -- | 0.5102 | -- | 0.3189 | -22.94 | -22.94 | 38.03 | 21.64 | 0.6382 | -- | 13.42 | 930,652.20 | -36.58 | -28.41 | -57.30 | -39.69 | -- | -- | -57.33 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| Avalo Therapeutics Inc | 1.93m | -31.54m | 13.70m | 19.00 | -- | 1.45 | -- | 7.12 | -381.36 | -381.36 | 6.94 | 9.11 | 0.0708 | 128.50 | 1.87 | 101,315.80 | -116.06 | -99.64 | -228.35 | -154.42 | 33.25 | 84.69 | -1,638.65 | -613.58 | 1.82 | -5.67 | 0.00 | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
| Microbot Medical Inc | 0.00 | -10.74m | 13.72m | 22.00 | -- | 2.48 | -- | -- | -1.08 | -1.08 | 0.00 | 0.3845 | 0.00 | -- | -- | 0.00 | -120.24 | -53.28 | -178.87 | -62.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.44 | -- | -31.76 | -- |
| X T L Biopharmaceuticals Ltd (ADR) | 0.00 | -1.78m | 13.74m | 0.00 | -- | 6.26 | -- | -- | -0.327 | -0.327 | 0.00 | 0.4074 | 0.00 | -- | -- | -- | -53.90 | -21.36 | -57.31 | -22.20 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.20 | -- | -- | -- |
| Nexgel Inc | 4.09m | -3.16m | 13.76m | 19.00 | -- | 2.70 | -- | 3.37 | -0.5566 | -0.5566 | 0.7212 | 0.818 | 0.4027 | 3.81 | 9.57 | 215,263.20 | -31.39 | -44.61 | -38.80 | -56.19 | 15.16 | 5.02 | -77.95 | -180.98 | 1.46 | -- | 0.1396 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
| Psyence Biomedical Ltd | 0.00 | 1.52m | 13.79m | -- | -- | -- | 9.10 | -- | -0.0442 | -0.0442 | 0.00 | -0.3979 | 0.00 | -- | -- | -- | 1.13 | -- | 1.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.63 | -- | -- | -- |
| Enzolytics Inc | 0.00 | -119.19k | 13.96m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| Vicapsys Life Sciences Inc | 0.00 | -1.08m | 14.24m | 2.00 | -- | -- | -- | -- | -0.0327 | -0.0327 | 0.00 | -0.0416 | 0.00 | -- | -- | 0.00 | -364.66 | -- | -- | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- | -- | -317.25 | -- | -- | -- |
| Mannatech Inc | 131.96m | -2.24m | 14.38m | 213.00 | -- | 1.35 | -- | 0.109 | -1.21 | -1.21 | 70.53 | 5.64 | 2.92 | 1.99 | 854.08 | 619,507.10 | -4.96 | 4.39 | -12.90 | 9.16 | 77.95 | 77.87 | -1.70 | 1.72 | 0.5093 | -5.81 | 0.1226 | 88.33 | -3.83 | -5.33 | 50.13 | -- | -20.38 | -- |
Data as of May 08 2024. Currency figures normalised to X T L Biopharmaceuticals Ltd's reporting currency: US Dollar USD
4.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Noked Capital Ltd.as of 31 Dec 2023 | 198.89k | 3.65% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 39.77k | 0.73% |
| BNP Paribas Financial Marketsas of 31 Mar 2024 | 300.00 | 0.01% |
| UBS Securities LLCas of 31 Dec 2023 | 54.00 | 0.00% |
| Central Trust Co. (Missouri)as of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
